|
|
||||||||
We have characterized four murine monoclonal antibodies (mAbs) to the extracellular domain of the human TSH receptor (TSH-R.E), the target autoantigen of Graves' disease. Recombinant TSH-R.E used as immunogen, was produced in E. coli as a fusion protein with glutathione-S-transferase or in a baculovirus-insect cell system, as a non-fusion glycoprotein. To increase the epitope specificity of the mAbs, two different strains of mice (H-2b and H-2d) were immunized. The epitopes recognized by the mAbs were characterized by immunoblotting with various recombinant constructs of TSH-R.E and by binding to overlapping synthetic peptides of the receptor. The four IgG mAbs characterized recognized epitopes localized to different regions on the TSH-R.E; amino acids 22–35 (A10 and All, both IgG2b from H-2b animals), amino acids 402–415 (A7, IgG2b from H-2b animals) and amino acids 147–228 (A9, IgG1 from H-2d animals). Immunolocalization studies showed that mAb A9 recognized TSH-R.E on unfixed cryostat sections, where binding was localized to the basolateral plasma membrane of thyroid follicular cells, suggesting that this antibody reacts with the native receptor on thyroid cells. The binding of the mAbs A7, A10 and All was also restricted to the basal surface of thyroid cells, but only after acetone fixation of the sections, implying that the epitopes recognized on the amino and carboxyl terminus of the extracellular region of the receptor are not accessible on the native molecule. None of the mAbs stimulated cyclic AMP responses in COS-7 cells transiently transfected with full-length functioning TSH-R.E, whilst weak inhibition of binding of radiolabelled TSH to porcine membranes in a radioreceptor assay was apparent with mAb A10 and All, but only at high concentrations of IgG. The ability of mAb A9 to bind to the native receptor without stimulating activity or inhibition of TSH binding suggests that antibody can bind to the central region of the TSH-R.E without perturbing receptor function. The availability of mAbs that recognize epitopes on different regions of the extracellular domain of TSH-R will lead to a better understanding of the autoantigenic regions on TSH-R implicated in disease activity.
This article has been cited by other articles:
![]() |
J. A. Gilbert, A. G. Gianoukakis, S. Salehi, J. Moorhead, P. V. Rao, M. Z. Khan, A. M. McGregor, T. J. Smith, and J. P. Banga Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways. J. Immunol., April 15, 2006; 176(8): 5084 - 5092. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. McLachlan, Y. Nagayama, and B. Rapoport Insight into Graves' Hyperthyroidism from Animal Models Endocr. Rev., October 1, 2005; 26(6): 800 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Estienne, N. Brisbarre, S. Blanchin, J.-M. Durand-Gorde, P. Carayon, and J. Ruf An in vitro model based on cell monolayers grown on the underside of large- pore filters in bicameral chambers for studying thyrocyte-lymphocyte interactions Am J Physiol Cell Physiol, December 1, 2004; 287(6): C1763 - C1768. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Muehlberg, J. A. Gilbert, P. V. Rao, A. M. McGregor, and J. P. Banga Dynamics of Thyroid-Stimulating and -Blocking Antibodies to the Thyrotropin Receptor in a Murine Model of Graves' Disease Endocrinology, April 1, 2004; 145(4): 1539 - 1545. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Schwarz-Lauer, P. N. Pichurin, C.-R. Chen, Y. Nagayama, C. Paras, J. C. Morris, B. Rapoport, and S. M. McLachlan The Cysteine-Rich Amino Terminus of the Thyrotropin Receptor Is the Immunodominant Linear Antibody Epitope in Mice Immunized Using Naked Deoxyribonucleic Acid or Adenovirus Vectors Endocrinology, May 1, 2003; 144(5): 1718 - 1725. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. V. Rao, P. F. Watson, A. P. Weetman, G. Carayanniotis, and J. P. Banga Contrasting Activities of Thyrotropin Receptor Antibodies in Experimental Models of Graves' Disease Induced by Injection of Transfected Fibroblasts or Deoxyribonucleic Acid Vaccination Endocrinology, January 1, 2003; 144(1): 260 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Marians, L. Ng, H. C. Blair, P. Unger, P. N. Graves, and T. F. Davies Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice PNAS, November 26, 2002; 99(24): 15776 - 15781. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Metcalfe, N. Jordan, P. Watson, S. Gullu, M. Wiltshire, M. Crisp, C. Evans, A. Weetman, and M. Ludgate Demonstration of Immunoglobulin G, A, and E Autoantibodies to the Human Thyrotropin Receptor Using Flow Cytometry J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1754 - 1761. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Chazenbalk, S. M. McLachlan, P. Pichurin, X.-M. Yan, and B. Rapoport A Prion-Like Shift between Two Conformational Forms of a Recombinant Thyrotropin Receptor A-Subunit Module: Purification and Stabilization Using Chemical Chaperones of the Form Reactive with Graves' Autoantibodies J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1287 - 1293. [Abstract] [Full Text] |
||||
![]() |
M. F. Prummel, L. J. S. Brokken, G. Meduri, M. Misrahi, O. Bakker, and W. M. Wiersinga Expression of the Thyroid-Stimulating Hormone Receptor in the Folliculo-Stellate Cells of the Human Anterior Pituitary J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4347 - 4353. [Abstract] [Full Text] |
||||
![]() |
Y. Nagayama, E. Nishihara, H. Namba, S. Yamashita, and M. Niwa Identification of the Sites of Asparagine-Linked Glycosylation on the Human Thyrotropin Receptor and Studies on Their Role in Receptor Function and Expression J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 404 - 409. [Abstract] [Full Text] |
||||
![]() |
M. Crisp, K. J. Starkey, C. Lane, J. Ham, and M. Ludgate Adipogenesis in Thyroid Eye Disease Invest. Ophthalmol. Vis. Sci., October 1, 2000; 41(11): 3249 - 3255. [Abstract] [Full Text] |
||||
![]() |
K. Tanaka, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport Subunit Structure of Thyrotropin Receptors Expressed on the Cell Surface J. Biol. Chem., November 26, 1999; 274(48): 33979 - 33984. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Suzuki, A. Mori, J. Saito, E. Moriyama, L. Ullianich, and L. D. Kohn Follicular Thyroglobulin Suppresses Iodide Uptake by Suppressing Expression of the Sodium/Iodide Symporter Gene Endocrinology, November 1, 1999; 140(11): 5422 - 5430. [Abstract] [Full Text] |
||||
![]() |
P. Graves, A. Pritsker, and T. F. Davies Post-Translational Processing of the Natural Human Thyrotropin Receptor: Demonstration of More than Two Cleavage Sites J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2177 - 2181. [Abstract] [Full Text] |
||||
![]() |
T. Akamizu, K. Moriyama, M. Miura, M. Saijo, F. Matsuda, and K. Nakao Characterization of Recombinant Monoclonal Antithyrotropin Receptor Antibodies (TSHRAbs) Derived from Lymphocytes of Patients with Graves' Disease: Epitope and Binding Study of Two Stimulatory TSHRAbs Endocrinology, April 1, 1999; 140(4): 1594 - 1601. [Abstract] [Full Text] |
||||
![]() |
M. Kita, L. Ahmad, R. C. Marians, H. Vlase, P. Unger, P. N. Graves, and T. F. Davies Regulation and Transfer of a Murine Model of Thyrotropin Receptor Antibody Mediated Graves' Disease Endocrinology, March 1, 1999; 140(3): 1392 - 1398. [Abstract] [Full Text] |
||||
![]() |
G. D. Chazenbalk, Y. Wang, J. Guo, J. S. Hutchison, D. Segal, J. C. Jaume, S. M. McLachlan, and B. Rapoport A Mouse Monoclonal Antibody to a Thyrotropin Receptor Ectodomain Variant Provides Insight into the Exquisite Antigenic Conformational Requirement, Epitopes and in Vivo Concentration of Human Autoantibodies J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 702 - 710. [Abstract] [Full Text] |
||||
![]() |
S. Mukherjee, K. Palczewski, V. Gurevich, J. L. Benovic, J. P. Banga, and M. Hunzicker-Dunn A direct role for arrestins in desensitization of the luteinizing hormone/choriogonadotropin receptor in porcine ovarian follicular membranes PNAS, January 19, 1999; 96(2): 493 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nagayama, H. Namba, N. Yokoyama, S. Yamashita, and M. Niwa Role of Asparagine-linked Oligosaccharides in Protein Folding, Membrane Targeting, and Thyrotropin and Autoantibody Binding of the Human Thyrotropin Receptor J. Biol. Chem., December 11, 1998; 273(50): 33423 - 33428. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text] |
||||
![]() |
K. Tanaka, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport Thyrotropin Receptor Cleavage at Site 1 Does Not Involve a Specific Amino Acid Motif but Instead Depends on the Presence of the Unique, 50 Amino Acid Insertion J. Biol. Chem., January 23, 1998; 273(4): 1959 - 1963. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Chazenbalk, J. C. Jaume, S. M. McLachlan, and B. Rapoport Engineering the Human Thyrotropin Receptor Ectodomain from a Non-secreted Form to a Secreted, Highly Immunoreactive Glycoprotein That Neutralizes Autoantibodies in Graves' Patients' Sera J. Biol. Chem., July 25, 1997; 272(30): 18959 - 18965. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Chazenbalk, K. Tanaka, Y. Nagayama, A. Kakinuma, J. C. Jaume, S. M. McLachlan, and B. Rapoport Evidence That the Thyrotropin Receptor Ectodomain Contains Not One, But Two, Cleavage Sites Endocrinology, July 1, 1997; 138(7): 2893 - 2899. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Vlase, N. Matsuoka, P. N. Graves, R. P. Magnusson, and T. F. Davies Folding-Dependent Binding of Thyrotropin (TSH) and TSH Receptor Autoantibodies to the Murine TSH Receptor Ectodomain Endocrinology, April 1, 1997; 138(4): 1658 - 1666. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Jaume, A. Kakinuma, G. D. Chazenbalk, B. Rapoport, and S. M. McLachlan Thyrotropin Receptor Autoantibodies in Serum Are Present at Much Lower Levels Than Thyroid Peroxidase Autoantibodies: Analysis by Flow Cytometry J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 500 - 507. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Bobovnikova, P. N. Graves, H. Vlase, and T. F. Davies Characterization of Soluble, Disulfide Bond-Stabilized, Prokaryotically Expressed Human Thyrotropin Receptor Ectodomain Endocrinology, February 1, 1997; 138(2): 588 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mukherjee, V. V. Gurevich, J. C. R. Jones, J. E. Casanova, S. R. Frank, E. T. Maizels, M.-F. Bader, R. A. Kahn, K. Palczewski, K. Aktories, et al. The ADP ribosylation factor nucleotide exchange factor ARNO promotes beta -arrestin release necessary for luteinizing hormone/choriogonadotropin receptor desensitization PNAS, May 23, 2000; 97(11): 5901 - 5906. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |